Clinical Scorecard: Telehealth-Enabled Subcutaneous Ketamine Treatment at Home: Evaluating Safety, Feasibility, and Clinical Outcomes in Adults with Moderate to Severe Depression, Anxiety, or PTSD in a Diverse U.S. Cohort - A Retrospective Study

At a Glance

Key Highlights

• Telehealth adoption increased due to COVID-19, improving access to mental health care.
• Standard of care delivered via telemedicine is comparable to in-person care.
• Significant treatment gaps exist for MDD, anxiety disorders, and PTSD.
• Fewer than 50% of patients respond to first-line therapies for depression and anxiety.
• High rates of nonresponse and dropout in PTSD treatments.

Guideline-Based Recommendations

Diagnosis

• Utilize standardized assessment tools for MDD, anxiety disorders, and PTSD.

Management

• Consider telehealth options for delivering evidence-based treatments.

Monitoring & Follow-up

• Regular follow-up assessments to evaluate treatment efficacy and adherence.

Risks

• Monitor for potential side effects and treatment discontinuation.

Patient & Prescribing Data

Adults with moderate to severe mental health conditions.

High rates of unfilled prescriptions and early discontinuation of therapy.

Clinical Best Practices

• Enhance access to mental health professionals through telehealth.
• Implement strategies to improve adherence to prescribed treatments.
• Utilize a patient-centered approach in treatment planning.

Related Resources & Content

• Chen et al. 2025
• Liu et al. 2020
• Alonso et al. 2018
• Thornicroft et al. 2017